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 Abstract 
 Objective. To investigate whether tailored evidence-based drug information (EBDI) to general practitioners (GPs) can 
change the proportion of ACE inhibitor prescriptions more effectively than EBDI provided as usual three and six months 
after the intervention.  Design . Randomized controlled trial.  Setting . GPs in southern Sweden working at primary health care 
centres (PHCCs) in seven drug and therapeutic committee areas.  Intervention . EBDI tailored to motivational interviewing 
(MI) technique and focused on the benefi t aspect was compared with EBDI provided as usual.  Subjects . There were 408 
GPs in the intervention group and 583 GPs in the control group.  Main outcome measures . Change in proportion of ACE 
inhibitor prescriptions relative to the sum of ACE inhibitors and angiotensin receptor blockers, three and six months after 
the intervention.  Results . The GPs ’ average proportions of prescribed ACE inhibitors increased in both groups. No statisti-
cally signifi cant differences in the change of proportions were found between intervention and control groups. Information 
was provided to 29% of GPs in both groups.  Conclusion . This study could not prove that specially tailored EBDI using MI 
implements guidelines more effectively than EBDI provided as usual. 
 Key Words:  Benefi t aspects ,  drug information services ,  drug prescriptions ,  evidence-based medicine ,  general practice ,  general 
practitioner ,  motivational interviewing ,  primary health care ,  Sweden 
mildly, 30% moderately, and 10% severely elevated 
blood pressure [5]. In a study it was estimated that 
as many as 80% could be unsatisfactorily treated, 
entailing increasing risks [6]. New expensive drugs 
augment the discussion on cost-effectiveness [5,7]. 
The number of prescriptions of angiotensin II  receptor 
blockers (ARB) increased in Sweden prior to studies 
of the effectiveness [8]. They were considered too 
expensive and without major benefi ts compared with 
angiotensin-converting enzyme (ACE) inhibitors [5]. 
A Danish study showed that there was no clear asso-
ciation between GPs ’ clinical interest and their 
 prescribing of new drugs such as ARB [9]. The Phar-
maceutical Benefi ts Agency introduced limitations on 
 Introduction 
 Prescribed medication accounted for approximately 
10% of resources used in Swedish health care in 
2005 [1,2]. In view of steeply rising drug prices, 
various measures to limit prescription have been 
taken [1]. Swedish general practitioners (GPs) 
account for more than 50% of all drug prescriptions 
[3] indicating the importance of their knowledge in 
evidence-based medicine (EBM) [4]. The guideline 
on hypertension from the Swedish Council on Tech-
nology Assessment in Health Care (SBU) [5] is an 
EBM source. 
 The prevalence of hypertension has been esti-
mated at 1.8 million (27%) Swedish adults; 60% with 
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ARB prescriptions with proposed savings of SKr 250 
million ( € 28 million,  $ US 36 million) annually. The 
SBU ’ s recommendations [5] for moderate hyperten-
sion (   140/90) were; (a) encourage lifestyle changes, 
(b) prescribe low doses of one of the following drugs: 
thiazides, ACE inhibitors, calcium-blocking agents, 
and beta blockers; beta blockers were later down-
graded to third-line treatment [10], (c) increase or 
add a low dose of the other drugs until acceptable 
blood pressure was attained, (d) ARB should only be 
used as a last-line drug. 
 Most drug information emanates from pharma-
ceutical companies [11] and is often too abundant 
[12,13]. In Sweden, evidence-based drug informa-
tion (EBDI) to GPs is frequently provided by non-
commercial medical information offi cers (MIOs) 
from the drug and therapeutic committees (DTCs) 
[14], funded by the county councils. 
 A Welsh qualitative study highlighted the com-
plexity in drug prescribing [15]. Not one method [16] 
but a combination is preferable to modify prescribing 
behaviour [17]. A recent Swedish randomized con-
trolled trial (RCT) among elderly patients showed no 
improvements in the patients ’ quality of life when a 
prescription review was sent to the physician or to the 
physicians and to the patients themselves, compared 
with a control group [18]. According to a health tech-
nology assessment report [19] dissemination of 
printed educational materials, audit with feedback, 
and multifaceted interventions with educational out-
reach improve physician performance by 6 – 8% 
whereas reminders have twice the impact. 
 In a focus-group study, GPs ’ thoughts on EBM 
and drug prescribing were related to benefi t and 
results [20]. The core category was found to be: 
prompt and pragmatic benefi t, delivered immedi-
ately, useful, and handy. 
 Motivational interviewing (MI) [21] is a change-
oriented, client-centred, and governing methodol-
ogy mainly used in the area of lifestyle change. 
Interest in the use of MI in Swedish health care is 
increasing [22]. 
 The aim of this study was to investigate whether 
tailored EBDI using MI, based on previous fi ndings 
on GPs ’ thoughts on prompt and pragmatic benefi t, 
can change GPs ’ prescribing pattern of ACE inhibi-
tors more effectively than EBDI provided as usual. 
 Material and methods 
 An enquiry regarding participation was sent to all 29 
Swedish DTCs; seven chose to participate. The MIOs 
of the seven DTCs, seven men and seven women 
(three GPs, 11 pharmacists), were previously assigned 
to provide information to GPs at specifi ed PHCCs in 
the participating DTCs. The offi cers were matched 
pairwise as far as possible based on profession, number 
of GPs in their district, and sex; male and female phar-
macists with an equal number of GPs in their domain, 
a female pharmacist offi cer with a female GP offi cer, 
and a male GP offi cer to a female GP offi cer. They 
were then randomized by an independent person. The 
GPs, the study objects, were as a result  “ cluster ran-
domized ” with their offi cer. There were 408 GPs in the 
intervention group and 583 in the control group. 
 Four male and three female offi cers (one GP, 
six pharmacists) provided tailored EBDI by using 
a motivational interviewing technique whereas 
three male and four female offi cers (two GPs and 
fi ve pharmacists) provided EBDI as usual. In two 
DTCs the randomization resulted in control and 
intervention offi cers in the same DTC but never at 
the same PHCC. 
 The offi cers gathered in October 2004 and were 
lectured on the guideline on hypertension. Those 
randomized to provide benefi t-tailored information 
[20] by using MI [21] were further trained for eight 
hours. The point of departure for the training was 
the individual GP ’ s own thoughts and beliefs and the 
benefi t aspects were emphasized. The method resem-
bles that of patient-centred communication [23]. 
The MI training included role playing, which was 
videotaped [21], and the offi cers were given feed-
back. All offi cers were invited to cooperate within 
their own offi cer group. They were aware that a dif-
ference between the groups existed but did not know 
what constituted the difference. No one in either 
group had experienced a motivational interviewing 
technique before the study. 
 In data compilation we found 1031 physicians 
working at the PHCCs before and after the inter-
vention. The majority were temporary doctors and 
substitutes. Statistics were calculated on all the 
 physicians who worked at the PHCCs and who pre-
scribed anti-hypertensive drugs during the study 
period. All physicians are referred to as GPs. 
 This study investigates whether the implemen-
tation of evidence-based drug information to 
general practitioners can be improved. 
 There were no differences between drug  •
information tailored with motivational inter-
viewing focused on the benefi t aspect and 
drug information provided as usual. 
 The fi nding is in accordance with Cochrane  •
reports on the use of motivational interview-
ing technique. 
 Use of motivational interviewing in drug  •
information has not previously been investi-
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 The intervention took place in November 2004. 
All GPs present at the 66 participating PHCCs, 28 
in the intervention group and 38 in the control group, 
were presented with the new guidelines during a two 
hour session. The intervention group received EBDI 
using MI and tailored to GPs ’ thoughts on prompt 
and pragmatic benefi t, while the control group 
received EBDI as usual. 
 Prescription data from participating PHCCs for 
all antihypertensive drugs were collected from their 
computerized medical records according to the Ana-
tomical Therapeutic Chemical Classifi cation. The 
software systems for computerized medical records 
were Profdoc  ®  , Medidoc  ®  , and Swedestar  ®  . Change 
in prescription from baseline (0 – 3 months before 
intervention) to the time periods 0 – 3 months and 
4 – 6 months after the intervention were analysed. A 
separate fi le enabled linkage between data on pre-
scription data and the prescriber. 
 The primary outcome was changed in the pro-
portion of ACE inhibitor prescriptions relative to the 
sum of ACE inhibitors and ARB, comparing inter-
vention and control groups during the two periods 
after the intervention. 
 A sample size calculation indicated that we needed 
an estimated total of 460 GPs (p    0.05, power 90%); 
991 were analysed. Statistics were calculated on the 
level of GPs. 
 Data were collected on several levels: (1) GPs ’ pre-
scriptions of antihypertensive drugs, (2) GPs, (3) 
PHCCs, and (4) geographical area including several 
PHCCs. Prescriptions were aggregated to produce just 
one change in proportion for each GP. A multilevel 
model was used to examine the effect of the levels 
 PHCC and  geographical area on the change in  proportion 
of GPs ’ ACE inhibitor prescriptions. As these  levels 
explained less than 1% of the variation in the depen-
dent variable/change in proportion of ACE inhibitor 
prescriptions, we decided to use the simpler multiple 
linear regression to compare the groups. The dependent 
variable was the change in GPs ’ prescription proportion 
while independent variables were group allocation and 
those variables where groups differed at baseline: 
patients ’ sex and type of clinic. The analysis was per-
formed by intention-to-treat and per protocol. 
 The multilevel modelLing was made in the 
 statistical program STATA. The multiple linear 
regression analyses were made in Epi-info 3.4.3 
(CDC, Atlanta, USA). 
 Results 
 Of the 1031 GPs, 40 were not present at the time 
of study. Thus 408 GPs were allocated to interven-
tion and 583 to control by randomization (Figure 1). 
At baseline there were more GPs working at private 
clinics in the intervention group and the average 
proportion of female patients was higher in the con-
trol group (Table I). 
 The proportion of ACE inhibitor prescriptions 
(average proportion for GPs) was increased in both 
groups at the three- and six-month follow-up. There 
were no signifi cant differences in the change in pre-
scription proportion between groups either with 
intention-to-treat (Table II) or per protocol analysis 
(Table III). Some 29% of the GPs received allocated 
information both in the intervention (117/408) and 
in the control group (168/583). 
 Discussion 
 In this RCT we have investigated whether EBDI tai-
lored with MI and focused on the benefi t aspect 
implements guidelines to GPs more effectively than 
EBDI provided as usual. The same relative increase 
in ACE inhibitor prescriptions was found in both 
groups during the two periods 0 – 3 and 4 – 6 months 
after the intervention. 
 One of the strengths of the study is that a high 
percentage % (94; 62 out of 66) of the PHCCs com-
pleted the study by submitting data. Another strength 
was that the proportion of female GPs in our study 
(41%) was similar to that among physicians in Swe-
den 2004 – 2005 (38%) [24]. Further, 4.2 million of 
9.1 million Swedish inhabitants live in the geograph-
ical area of the study representing large and medium-
sized cities as well as rural areas. 
 Finally the MIOs, while aware that there was a 
difference between the groups, were not aware of 
what constituted the difference. 
 The limitations of our study are several: seven of 
the 29 DTCs took part; the others were occupied 
with other projects, or lacked time or employees to 



























































70 I. Skoglund et al. 
participate. The possibility of selection bias cannot 
be ignored. It was not possible for us to have control 
of how the information was provided to the GPs and 
the time for the tailored education might have been 
insuffi cient. Statistics were calculated on all the phy-
sicians who worked at the PHCCs and who pre-
scribed anti-hypertensive drugs during the study 
period. We do not know to what extent those not 
present during the information-giving were reached 
by the information provided. 
 All prescriptions, both ongoing drug treatment 
prescribed by telephone and at a GP visit and those 
just initiated, were analysed. This might dilute the 
effect of change as is described in a North American 
mini-review [25]. The outcome was dependent on 
how the message on the use of ARBs was received. 
The other messages, except for the changed status of 
beta-blockers [10], were well known. The ARB mes-
sage might have had a stronger impact if there were 
less competition in time use [25]. However, the issue 
of how to prescribe ARBs was well known before-
hand by Swedish GPs from the medical debate. 
 The relative increase in the number of prescribed 
ACE inhibitors is in line with the recommendations 
from the SBU [5]. Because the numbers of pre-
scribed ARB and ACE inhibitors has increased con-
tinuously since the year 2000 [8], it cannot be 
determined whether the increase in the number of 
ACE inhibitors prescriptions can be attributed to our 
intervention or not. Possible interpretations of the 
study results could either be equal impact of the 
information in both groups, no impact of the infor-
mation in either group, or a combination of both 
explanations. 
 Motivational interviewing is described in the 
 literature as an evidence-based method for lifestyle 
change, especially with regard to alcohol  consumption 
[26,27]. In a review of RCTs on substance abuse, 
including alcohol, [28] MI as a brief individual inter-
vention (1 – 4 sessions) signifi cantly reduced abuse 
compared with no intervention; no signifi cant differ-
ences were seen compared with treatment as usual. 
A meta-analysis of RCTs on MI compared with 
treatment as usual mainly in primary health care [29] 
showed signifi cant effects on body mass index, 
 systolic hypertension, total blood cholesterol, and 
alcohol measurement in about 75% of patients. 
However, the  “ as usual ” in this study meant a 
 Table I. Baseline characteristics of 991 GPs in the intervention and control groups at baseline. 
Intervention group 
(n    408)
Control group 
(n    583)
Difference between 
groups  (p-value)
Medical information offi cers 1 6 pharmacists, 1 GP 
 4 males, 3 females
5 pharmacists, 2 GPs 
 3 males, 4 females
 – 
Primary healthcare centres 28 38  – 
GPs ’ age; years 2 46 (11) 47 (11) 0.19
GPs ’ sex; male/female 3 248/153 328/250 0.13
Number of GPs working at private/public clinic 3 31/377 0/583    10 6 
Proportion of GPs receiving allocated treatment 3 29% 29% 0.96
Average proportion of female patients among GPs ’ patients 2 0.54 (0.19) 0.57 (0.20)  0.016 
Average age of GPs ’ patients; years 1 69 (6.5) 68 (6.4) 0.13
 Notes:  1 Description of medical information offi cers ’ profession (fi rst line) and sex (second line).  2 Mean (standard deviation). Difference 
between groups analysed with Student ’ s t-test.  3 Difference between groups analysed with chi-squared with Yates correction. Signifi cant 
differences are shown in bold. 
 Table II. Proportion of ACE inhibitors prescribed by all GPs and change in this proportion 
over time (intention-to-treat). 
Intervention group Control group
n    408 n    583
Proportion of ACE  inhibitors at 3 months before 
intervention, baseline 1, 2 
0.64 (0.26)
 0.67 (0.50 – 0.83)
0.63 (0.28)
 0.65 (0.45 – 0.85)
Relative change in proportion of ACE inhibitors 
0 – 3 months after intervention 2,3 
   0.12 (0.43)
   0.029 ( – 0.11 – 0.32)
   0.12 (0.59)
   0.00 ( – 0.17 – 0.27)
Relative change in proportion of ACE inhibitors 
4 – 6 months after intervention 2,3 
   0.12 (0.47)
   0.051 ( – 0.13 – 0.25)
   0.13 (0.56)
   0.0040 ( – 0.14 – 0.26)
 Notes:  1 Proportion    number of ACE inhibitors prescribed divided by the sum of ACE inhibitors and 
ARBs.  2 Upper line means (standard deviation). Lower line median (interquartile range).  3 Relative 
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 GP-centred approach. This is not regarded as the 
 “ gold standard ” in contemporary patient consulta-
tions [30]. Patient education using MI on diabetes 
by nurses [22] rendered no improvements on HbA1c 
compared with education as usual. 
 One major difference between our study and 
others is that GPs were informed in a group instead 
of individually. Another difference is that GPs  differ 
from patients, having a different pre-understanding 
of the context than patients. In this study, the GPs 
were informed in a group and had a different rela-
tionship to the information provider than patients 
have to a care provider. However, an interesting 
similarity is that as in the review on MI and sub-
stance abuse [28] no differences were seen bet-
ween MI and treatment as usual. A plausible 
explanation of the results in our study is that MI 
and other interventions share non-specifi c thera-
peutic factors, such as attention and therapeutic 
alliance, which might contribute to 30% of the 
effect [31]. 
 Conclusion 
 This study could not prove that specially tailored 
EBDI using MI to GPs changes the outcome more 
than EBDI provided as usual. 
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